Combined parecoxib and I.V. paracetamol provides additional analgesic effect with better postoperative satisfaction in patients undergoing anterior cruciate ligament reconstruction

Zeinab Ahmed Elseify1, Salwa Omar El-Khattab2, Ahmed Metwally Khattab3,4, Eman Mohammed Atta1,4, Layal Fares Ajjoub3

1AL-Ahli Hospital, Doha, Qatar, 2AinShams University, Cairo, Egypt, 3Doha Clinic Hospital, Doha, Qatar, 4Elzagazig University, Elzagazig, Egypt

ABSTRACT

Background: Adequacy of postoperative analgesia is one of the most important factors that determine early hospital discharge and patients’ ability to resume their normal activities postoperatively. The optimal non-opioid analgesic technique for postoperative pain management would reduce pain and enhance patient satisfaction, and it also facilitates earlier mobilization and rehabilitation by reducing pain-related complications after surgery. The aim of this study was to evaluate the analgesic efficacy of intravenous paracetamol and parecoxib when used alone, or in combination. Methods: Sixty American Society of Anesthesiology (ASA) physical status I and II adult patients who were scheduled for anterior cruciate ligament reconstruction were included in this study. Patients were allocated into three groups: group I patients received 1 g intravenous paracetamol after induction and another 1 g 4 h later, group II received 40 mg parecoxib after induction, while group III received combination of both drugs (paracetamol 1 g and parecoxib 40 mg). Pain during rest and mobility was assessed in the immediate postoperative period, 2 h and 8 h successively using visual analog scale (VAS). Patient satisfaction was rated according to satisfaction score. Results: Total morphine requirements were lower in group III patients (6.9 ± 2.7 mg) in comparison to group I patients (12.6 ± 3.6 mg) or group II patients (9.8 ± 2.8 mg). The least VAS scores were recorded during knee movement (3.8 ± 1.1) in group III patients compared to group I (6.0 ± 1.8) and group II patients (4.8 ± 1.9). Eight hours postoperatively, group III patients were more satisfied regarding the postoperative pain management. Conclusion: Combination of intravenous paracetamol and parecoxib provided better analgesia and higher patient satisfaction than each drug when used separately.

Key words: Intravenous paracetamol, parecoxib, postoperative analgesia

INTRODUCTION

Despite the availability of various therapeutic approaches to pain management and an improved understanding of pain pathophysiology, acute postoperative pain continues to be undertreated or treated ineffectively. Proper pain management is essential for the early recovery and rehabilitation especially after knee surgery. Recent evidence suggests that this goal can be best achieved by using a combination of pre-emptive techniques involving both centrally and peripherally acting analgesic drugs and devices.[1] Opioids are effective analgesics, but their usefulness is limited by side effects, such as nausea and vomiting, somnolence, constipation, and respiratory depression.[2] Non-opioids (e.g., paracetamol, non-steroidal anti-inflammatory drugs NSAID, and local anesthetics) have opioid sparing effects.[3]

Cyclo-oxygenase (COX)-2 selective inhibitor drugs (coxibs) are thought to have beneficial effects on inflammation and pain with concomitant preservation of homeostatic function and reduction in the incidence of side effects as compared with nonselective NSAIDs. Parenteral formulations allow for intra-operative administration and...
may overcome the problem of bioavailability encountered with oral formulations within the perioperative setting. Parecoxib is the first injectable COX-2 selective inhibitor indicated for the treatment of acute postoperative pain.[10] It is an inactive pro-drug that undergoes rapid amidohydrolysis in vivo to the pharmacologically active, highly specific inhibitor of cyclooxygenase-2 (COX-2) enzyme, valdecoxib.[11] Parecoxib and valdecoxib were not found to increase the risk of cardiovascular adverse events after non-cardiac surgery.[12] Paracetamol (acetaminophen) is an effective and safe analgesic used worldwide to relieve mild to moderate pain in conditions such as headache, toothache, and arthritis.[8] Acetaminophen and NSAIDs probably have different sites of action; their combined use may have additive or synergistic effect. The objective of this study was to compare the analgesic effect of parecoxib and intravenous paracetamol given separately or together on the early postoperative pain and to evaluate patients’ satisfaction in patients undergoing ACL under general anesthesia.

METHODS

After obtaining institutional approval (Doha Clinic Hospital-Doha-Qatar) and informed written consent, a prospective, randomized, double blind study was conducted from July 2007 through August 2008. Sixty ASA physical status I and II patients, aged between 18 and 45 years scheduled for elective ACL reconstruction surgery were participated in this study. Exclusion criteria were pregnancy, breast-feeding women, history of drug abuse, or allergy to any of the study medications, intake of narcotic analgesics, NSAIDs, or paracetamol within 24 h before the study. All patients were premedicated with 7.5 mg midazolam tablet 1 h before surgery. Patients enrolled in the study were randomly allocated by computer-generated random numbers to be divided into three groups: group I (paracetamol group) 20 patients, group II patients (parecoxib group) 19 patients, and group III (paracetamol-parecoxib group) 21 patients.

During the preoperative visit, each enrolled patient was asked to choose a sealed envelope with his code number inside. The name, file number, and body weight were recorded on the chosen sealed envelope. The envelopes were opened before the start of anesthesia. Anesthesia induction was performed with propofol (Diprivan® 1% Astra-Zeneca, Madrid) 2-3 mg/kg, Fentanyl 2 µg/kg induction dose, increments of Fentanyl were added according to the intraoperative requirements, cisatracurium (Nimbex®, Glaxo Smith Kline, S.A. Spain) 0.15 mg/kg. All patients were mechanically ventilated after insertion of laryngeal mask (LMA-Classic™) with 40:60 oxygen and nitrous oxide. Anesthesia was maintained with Sevoflurane (Abbott) 1.50±0.50 Vol%. Group I received 1 g IV Paracetamol (Perfalgan® 100 ml vial UPSA France) after induction and 1 g 4 h later, group II patients received 40 mg IV Parecoxib (Dynastat™ PHARMACIA) after induction, and group III patients received both parecoxib and paracetamol at induction and 1 g paracetamol after 4 h. Paracetamol was administered by slow infusion over 15 min, whereas parecoxib was injected as a rapid bolus. Each patient in groups I and II received the proposed drug and the placebo of the other drug. Operations were carried out by the same surgeon, who was blinded to the drugs administered. Local anesthetics were avoided in all patients under the study. At the end of the procedure, residual paralysis was antagonized with neostigmine and atropine if needed. After laryngeal mask removal, the patients were transferred to the post-anesthesia care unit (PACU). Pain intensity at rest and during active knee movement was assessed immediately upon full recovery in the PACU using a 10 cm visual analogue scale (VAS) {0 = no pain → 10 = worst imaginable pain}. IV morphine boluses (3 mg) were given and possibly repeated every 15 min with a maximum dose of 12 mg, until VAS 3 or less. Patients would not be discharged to the ward unless being awake and oriented, able to move all extremities on command, hemodynamically stable, respiratory stable (able to breathe deeply), oxygen saturation >90% on room air, no or mild discomfort, and with no or mild nausea but no vomiting. After leaving the PACU, pain was re-assessed during rest and active movement after 2 h and 8 h using VAS. Patient’s satisfaction with postoperative pain management was assessed at the 8th hour postoperatively with a 4-point rating scale (poor=0, fair=1, good=2, and excellent=3). IV morphine 3 mg was given upon request in cases of persistent pain until VAS 3 or less. Total doses of morphine given in the PACU and in the ward until 8 h were calculated. Flow chart of patients through the trial is shown in Figure 1.

Analysis of data was done by IBM computer using SPSS (statistical program for social science). The paired student t-test was used to compare quantitative data in the same group. One-way ANOVA test (analysis of variance) was used to compare more than two groups as regards quantitative variables. P value <0.05 was considered statistically significant.

RESULTS

Sixty patients (20 in the paracetamol group, 19 in the parecoxib group and 21 in the paracetamol–parecoxib group) were included from July 2007 through August 2008. Demographic data, procedure duration, intraoperative...
fentanyl consumption and duration of stay in PACU are presented in Table 1.

There were no inter-group differences in patients’ demographics, duration of surgery and intraoperative fentanyl consumption. There were statistically significant differences between group II (23.48±3.8 min) and group III (17.23±2.34 min) and high statistically significant difference between group I (31.35±4.39 min) and group III (17.23±2.34 min) with no statistically significant difference between group I (31.35±4.39 min) and group II (23.48±3.8 min) as regards the time of stay in PACU. Doses of morphine early postoperatively and total doses were lowest among group III patients (2.3±1.9 and 6.9±2.8 mg) which is then followed by group II (4.4±2.7 and 9.8±2.8 mg), and there was a high statistically significant difference between group III versus group I and group II and between group I, and group II by ANOVA test (P<0.01) as shown in Table 2.

In Table 3, VAS shows that during knee movement, group III patients had the lowest pain compared to the other two groups and also group II had less pain than group I with a high statistically significant difference between group III (3.8±1.1) versus both group I (6.0±1.8) and group II (4.8±1.9) and also a high statistically significant difference between I versus group II by ANOVA test (P<0.01). On the other hand, no statistically significant difference could be detected between the all groups as regards VAS during rest in the early postoperative period by the same test (P>0.05).

VAS values were higher during movements in comparison to rest within each group by the paired t-test (P<0.01), as shown in Table 4. After 8 h, no statistically significant difference could be detected between the all groups as regards VAS both during rest and movements.

Group III patients significantly considered pain management as good or excellent at the 8th hour postoperatively with more satisfaction than the other two groups (P>0.05), [Table 5]. Although there was no statistically significant difference between groups I and II, still there was clinical evidence of higher patient satisfaction in group II than in group I.

Table 1: Patient’s demographic and operative data

|                | Group I (Paracetamol group) | Group II (Parecoxib group) | Group III (Combined group) |
|----------------|-----------------------------|---------------------------|----------------------------|
| N              | 20                          | 19                        | 21                         |
| Age (year)     | 33.5±7.1                    | 33.4±6.8                  | 31.6±8.5                   |
| Body weight (Kg) | 74.9±5.9                    | 75.2±8.9                  | 76.4±9.8                   |
| Sex (male/female) | 37/1                       | 15/4                      | 18/3                       |
| Duration of surgery (min) | 57.8±6.5                  | 58.5±6.5                  | 55.3±7.2                   |
| Fentanyl consumption (µg) | 162±19.49                  | 160±52.4                  | 158±52.4, 15.4             |
| Stay in (PACU) (min) | 31.35±4.39                 | 23.4±3.8                  | 17.2±2.34*                |

*Significant (P<0.05), PACU = Post-anesthesia care unit.

Table 2: Changes in morphine doses within each group and difference between the studied groups at different intervals

|                | Early postoperative | After 2 h | After 8 h | Total morphine |
|----------------|---------------------|-----------|-----------|----------------|
| Group I N=20  | 7.05±2.6(b,c)       | 2.71±1.9  | 5.62±2.1  | 12.6±3.6(b,c)  |
| P              |                     | <0.001**  | >0.05     |                |
| Group II N=19 | 4.4±2.7(a,c)        | 3.5±1.8   | 5.42±6.6  | 9.8±2.8(a,c)   |
| P              |                     | <0.05*    | >0.05     |                |
| Group III N=21| 2.3±2.9(a,b)        | 2.1±1.9   | 4.62±0.3  | 6.9±2.7(a,b)   |
| P              |                     | >0.05     | <0.001**  |                |
| Significance   | F=22                | F=0.45    | F=1.5     | F=18           |
| test between   | P<0.001**           | P>0.05    | P>0.05    | P<0.001**      |
| the groups     |                      |           |           |                |
| (ANOVA test)   |                      |           |           |                |

* Significant test P<0.05, ** Highly significant P<0.01, a-group I, b-group II, c-group III.

Table 3: Changes in visual analogue scale within each group and differences between the studied groups during rest and movement at early postoperative period

|                | Resting | Movement | t    | P     |
|----------------|---------|----------|------|-------|
| Group I N=20  | 4.3±1.5 | 6.0±1.8(b,c) | 3.3  | <0.01**|
| Group II N=19 | 4.2±2.2 | 4.8±1.9(a,c) | 2.2  | <0.05* |
| Group III N=21| 3.2±2.2 | 3.8±1.6(a,b) | 1.2  | >0.05  |
| Significance test between the groups (ANOVA test) | F=1.8 | F=9.00 | P>0.05 | P<0.001** |

* Significant test P<0.05, ** Highly significant P<0.01, a-group I, b-group II, c-group III.
Table 4: Changes in visual analogue scale at rest and during movement within each group and difference between the studied groups as regard visual analogue scale at rest and movement at 2 h and 8 h interval

| The studied groups | Resting at 2 h postoperative | Resting 8 h postoperative | Movement 2 h postoperative | Movement 8 h postoperative |
|--------------------|-------------------------------|---------------------------|---------------------------|---------------------------|
| Group I N=20       | 3.1±1.7                       | 2.3±1.3                   | 4.5±1.9                   | 3.2±1.3                   |
| P                  | >0.05                         | <0.001**                  | >0.05                     | >0.05                     |
| Group II N = 19    | 2.3±1.7                       | 2.3±1.2                   | 4.3±1.7                   | 3.3±1.2                   |
| P                  | >0.05                         | <0.001**                  | >0.05                     | >0.05                     |
| Group III N= 21    | 2.1±1.5                       | 1.7±1.1                   | 3.8±1.7                   | 2.6±1.3                   |
| P                  | >0.05                         | <0.001**                  | >0.05                     | >0.05                     |
| Significance test  | F = 1.9, P>0.05               | F = 2.1, P>0.05           | F = 1.6, P>0.05           | F = 2.00, P>0.05          |
3. Aubrun F, Kalfon F, Mottet P, Bellanger A, Langeron O, Coriat P, et al. Adjunctive analgesia with intravenous propapacetamol does not reduce morphine-related adverse effects. Brit J Anaesth 2003;90:314-9.

4. Beaussier M, Weickmans H, Paugam C, Lavazais S, Baechle JP, Goater P, et al. A randomized, double-blind comparison between parecoxib sodium and propacetamol for parenteral postoperative analgesia after inguinal hernia repair in adult patients. Anaesth Analg 2005;100:1309-15.

5. Jodie B, Jayne E, Henery J, Andrew N. Oral Valdecoxibe and injected Parecoxib for acute post operative pain: a quantitative systemic review. BMC Anaesthesiol 2003;3:1-9.

6. Nag A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Brit J Anaesth 2003;90:746-9.

7. Schug SA, Joshi GP, Camu F, Pan S, Cheung R. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Anaesth Analg 2009;108:299-307.

8. Hugo V, Thys L, Luc V, Buerkle H. Assessing analgesia and repeated administrations of propacetamol for postoperative pain: comparison with morphine after dental surgery. Anaesth Analg 2004;98:159-65.

9. Issioui T, Klein KW, White PF, Watcha MF, Coloma M, Skrivaneck GD, et al. The efficacy of premedication with celecoxib and acetaminophen in preventing pain after otolaryngology surgery. Anaesth Analg 2002;94:1188-93.

10. Fletcher D, Nègre I, Barbin C, François A, Carreres C, Falgueirrettes C, et al. Postoperative analgesia with i.v. propacetamol and ketoprofen combination after disc surgery. Can J Anaesth 1997;44:479-85.

11. Siddik SM, Aouad MT, Jalbout MI, Rizk LB, Kamar GH, Baraka AS. Diclofenac and/or Propacetamol for post operative pain management after cesarean delivery in patients receiving patient controlled analgesia using morphine. Reg Anaesth Pain Med 2001;26:298-300.

12. Kiersch TA, Halladay SC, Hormel PC. A single-dose, double-blind comparison of naproxen sodium, acetaminophen, and placebo in postoperative dental pain. Clin Ther 1994;16:394-404.

13. Gehling M, Arndt C, Eberhart LH, Koch T, Krüger T, Wulf H. Postoperative analgesia with parecoxib, acetaminophen, and the combination of both: a randomized, double-blind, placebo controlled trial in patients undergoing thyroid surgery. Brit J Anaesth 2010;104:761-7.

14. Zhu X, Conklin D, Eisenach J. Preoperative inhibition of cyclooxygenase-1 in the spinal cord reduces postoperative pain. Anaesth Analg 2005;100:1390-3.

15. Bonnefont J, Courade JP, Lloui A, Eschalier A. Anti-noceceptive effect of paracetamol, In Drug-Special Issue, Vol. 63. Walter Kluwer Company; 2003. p. 1-51.

16. Gibbison B, Kinsella SM. Postoperative analgesia for gynecological laparoscopy. Saudi J Anaesth 2009;3:70-6.

Source of Support: Internal Resources of the Department of Anesthesia-Doha Clinic Hospital, Doha, Qatar. Conflict of Interest: None declared.